P53 toxicity is a hurdle to CRISPR/CAS9 screening and engineering in human pluripotent stem cells

Robert J. Ihry(Genomics Institute of the Novartis Research Foundation), Ajamete Kaykas(Metro Transit), Chaoyang Ye(Blueprint Medicines (United States)), John Reece-Hoyes(University of Massachusetts Chan Medical School), Daniel Ho(Novartis (United States)), Gregory McAllister, William C. Forrester(Cancer Research Center), Max R. Salick(Novartis (United States)), Kathleen A. Worringer(Johns Hopkins University), Kraig M. Theriault(Novartis (United States)), Ranjit Randhawa(Novartis (United States)), Zinger Yang(Broad Institute), Gregory R. Hoffman, Sravya Kommineni(Novartis (United States)), Marie Sondey(AbbVie (United States)), Julie Chen, Ricardo Dolmetsch(Novartis (United States)), Tripti Kulkarni(Novartis (United States)), Carsten Russ(Broad Institute), Elizabeth Frias(Novartis (United States))
bioRxiv (Cold Spring Harbor Laboratory)
July 26, 2017
10.1101/168443
Cited by 7

Related Papers

Structure, function and diversity of the healthy human microbiome
|Nature|2012|12k
A Draft Sequence of the Neandertal Genome
|Science|2010|4.6k
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells
|Nature|2007|4.2k
Determination and Inference of Eukaryotic Transcription Factor Sequence Specificity
|Cell|2014|2k
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
|Nature Biotechnology|2009|1.5k